Saturday, 28 February 2015

Budget updates_3 New NIPER institutes

Dear All,
Mr. Arun Jaitley, honorable finance minister during his budget today on 28th February 2015 announced the creation of three new "National Institutes of Pharmaceutical Education & Research (NIPER)" in three states namely Maharashtra, Rajasthan and Chhattisgarh.

A welcome initiative or dilution of the NIPER brand. Request your thoughts. Send your thoughts to

We would publish the same on the blog.

Friday, 27 February 2015

Pharma academic research - Indian patent applications published on 27th February 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
For details of these patents, please write back to us at
Indian patent applications published on 27th February 2015

Application No
Media for in vitro dissolution testing of polysaccharide based colon
targeted formulations and method thereof
2485/DEL/2013 A
1) Goud Niranjan Kotla
2) Gulati Monica
3) Singh Sachin Kumar
4) Basotra Mohit
5) Chaudhary Yashwant
Lovely Professional University (LPU), Phagwara, Punjab
Nanosilver Nano Hydrogel product as antimicrobial coating and additive
materials for healthcare devices
2469/DEL/2013 A
1) Bhuvanesh Gupta
2) Alok R Ray
3) Arti Kapil
4) Sadiya Anjum
5) Deepti Gautam
Department of Biotechnology, 
Indian Institute of Technology, Delhi
Development of cinnamon-cumin dual drug loaded poly (d,l-Lactide-Coglycolide)
coated polymeric nanoparticles for sustained release of anti-diabetic drugs
2474/DEL/2013 A
1) Aditi Sangal
2) Sunita Rattan
Amity University, Noida
Self Nano emulsifying drug delivery system for a ginger active principles
based composition
2496/DEL/2013 A
1) Kanchan Kohli
2) Abhinav Garg
3) Anoop Kumar
Jamia Hamdard
Superparamagnetic iron oxide Nanoparticle formulation as MRI negative
contrast enhancing agent for cancer detection of organs of the reticuloendothelial system
and process of its preparation thereof
2478/DEL/2013 A
1) Koul, Veena
2) Choudhary, Veena
3) Mahajan, Shweta
Indian Institute of Technology, Delhi

Thursday, 26 February 2015

It's a century for us

Dear All,

Greetings for the day. It is a pleasure to inform you that we have crossed the 100 subscribers' milestone today. If you can see on the feed-count tab today, we have got 100 subscribers.

We are very thankful to all of you for your support and wishes throughout the journey. The blog is surely serving the pharma community with some unique offerings of information and updates.
In the mean time, our back-end team is working to reach the maximum students, faculties and industry professionals. Many of you must have received the subscription request from our team. Now we have got subscribers from across the country and some of the who's who of the Indian pharma academics have joined us as subscribers. We also request the faculties to share the blog contents with their students as they would be equally benefited from the effort.
We would be coming with some novel ideas for you which would enhance the acceptability of the blog and create a resource for the students as well as faculties.
Because of confidentiality clauses, we can not disclose the identity of the bloggers as of now. Please write back to us at
Thanks and Regards,
Team Pharma Literati.

BMJ publishes three papers on medical malpractice, regulations and whistleblower protection in India

Today's Mint has report on malpractices in Indian healthcare sector. A must read for everyone who is bothered about the healthcare practices and pharmaceutical industry.

Please visit:

Irrational prescriptions, bribes for referrals and unnecessary investigations are the most common forms of corruption in India’s health sector, the British Medical Journal (BMJ) reported.
BMJ also addresses the complete lack of regulation of private players. Health is one of the least transparent and worst regulated sectors in India. A 2005 study by Transparency International concluded that the Indian healthcare sector is the second most corrupt sector, after the police.
Corruption, kickbacks and the nexus between doctors and pharmaceutical firms are so rampant that BMJ, in June 2014, launched a campaign called Corruption in Medicine, specific to India, stating in an editorial that corrupt practices had “steadily eroded the trust and respect with which doctors were previously regarded”.

CET Notification_2015/16 for M. Pharm admission

Directorate of Technical Education, Maharashtra State announced the dates for the Common Entrance Test for Admission to First Year of M. Pharmacy and B. Pharmacy.
The dates are as follows:

Date of Online CET
Master of Pharmacy
(M. Pharm.)
Sunday, 17th May 2015
Degree in Pharmacy
(B. Pharm.)
MT-CET 2015
Saturday, 25th April 2015 &
Sunday, 26th April, 2015.

The detailed notification will be published on the official website and in leading newspapers shortly.


Wednesday, 25 February 2015

Article of interest_Rethinking drug discovery

Subhadra Dravida, Founder and CEO of Tran-Scell Biologics& TranSTox BioApplications India and Prabhat Arya, Department of Organic and Medicinal Chemistry Dr. Reddy's Institute of Life Sciences (DRILS) University of Hyderabad Campus India write about the rethinking drug discovery. For full article, please visit:
Drug discovery is a tough business! At the same time, it is the domain that provides an opportunity to improve the quality of human health and allows recovering from the suffering due to various biological disorders. In the past decades, we have witnessed a major limitation in creating the next-generation drugs despite a significant boost in the financial spending for research and development.
As we have seen for the past several years, the current practice of drug discovery seems to be a losing battle and not much has come out to benefit the society that is desperately looking for next generation effective medicines at an affordable cost. We are hoping that through embracing some of these new research working models and building like-minded teams that are a nice blend of skill-sets from academia and pharma sector would allow reaching the objectives that are not possible to be achieved with classical working models. A challenging task is to build teams to undertake high-risk research programmes, and, this requires a deeper understanding of the need of so called ‘collective competence’. Only time will tell, whether, climbing this mountain would lead to a productive path that the patient community would benefit from, and this remains to be seen in days ahead!


Article of interest_Applying Quality by Design (QbD) principles to the development of analytical methods

Narendra Kumar, Assistant Professor Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education& Research Hyderabad, India writes about the application of Quality by design (QbD) principles to the development of analytical methods.
For the full articles, please visit:
The article highlights the application of Quality by Design principles to the analytical (HPLC) method development process. A marriage of HPLC with QbD is suggested for rapid and robust method development, understanding factors influencing chromatography, easier transfer of the method through proper documentation. The use of various modelling software programmes allowed a limited amount of experimental data to be used to examine a large number of probable run conditions. Once the optimum run conditions and their tolerance to change were predicted, experiments were run to confirm the predictions. This data in the future can on the one hand serve as a common medium of discussion between analysts and regulatory bodies and easily and quickly diagnose any problems which may be encountered during the lifecycle of the method.

Tuesday, 24 February 2015

Kiran Mazumdar Shaw's interview in Indian Express

Today's Indian Express carries an interview of Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon, India’s largest Biopharmaceuticals company.
The excerpts:
What’s the value and scope of Biotechnology studies and research in India or are there better prospects abroad?
If India can successfully tackle the gaps in infrastructure and challenges in the policy and funding domains, the country has a huge potential to become the leading global innovation hub for biotech.
Today, the essence of Biotechnology is most prominent in Genetic Research and Drug Designing. However, it is effectively being used for conservation of natural resources and developing newer sources of alternative energy, as well.
Which field of study (Genetic, Agricultural or Industrial) is gaining prominence?
Genetic Engineering has applications in Pharmaceuticals, Agriculture, Industrial Enzymes and Biometrics. Synthetic Biology is gaining great prominence in developing new diagnostics, novel vaccines and drugs and value-added nutritional and food ingredients.
How can India benefit from Biotechnology?
Biotechnology can play a significant role in meeting the economy’s challenges. As a significant stakeholder in India’s biotech journey, I see the following as the critical biotech objectives for India to be achieved by 2025: energy independence through bio-fuels; healthcare for all through vaccines, therapeutics and diagnostics; zero public defecation through bio-toilets; individual households and community toilets at `5,000 per toilet; zero landfills through bioconversion of solid waste to fuel and fertiliser; eradicate malnutrition through protein and vitamin supplements derived from genetically modified plants and microbial fermentation; two-fold increase in agricultural productivity through Biotechnology to create food surplus; de-pollute all rivers in India through bioremediation and green technologies; make polluting industries ‘green’ through Biotechnology; sewage treatment as a national mission through zero discharge effluent treatment technologies and eradicate vector-borne diseases like dengue, chikungunya and malaria.

Monday, 23 February 2015

Innovative concepts and methodologies in Pharmaceutical Research

H. R. Patel Institute of Pharmaceutical Education and Research is organizing one-day national seminar on  "Innovative concepts and methodologies in Pharmaceutical Research."
This  would be followed by Inauguration of Nanotech Unit and a research award competition for undergraduate students.

The details are as follows:

Theme:             Innovative concepts and methodologies in Pharmaceutical Research.

Dates:               4th March 2015.

Organized by:   H. R. Patel Institute of Pharmaceutical Education and Research . 

Location:           Shirpur (Maharashtra).

Details available at:

2 pharma colleges in Gujarat want to shut down

Ahmedabad Mirror reports the fate of technical education in Gujarat.
Two MBA institutes and two pharmacy colleges offering degree courses have applied for shutting down. Three MBA schools and a pharmacy college have applied for reduction in seats, citing less than adequate number of students. "None of the applications is from institutes in Ahmedabad. The colleges that have sent us applications are mostly from rural areas like Modasa, Matar, Mehsana and Kutch, to mention a few. Students do not opt for colleges in remote areas as many do not have adequate infrastructure, teachers and other facilities," said an official at GTU requesting anonymity.
Despite housing 40 per cent of pharmaceutical industries from India, students clearing BPharm and MPharm do not find lucrative jobs. Head of the department at LJ Institute of Pharmacy, Sheeraj Shah, said that the location of the institute also plays a crucial role. "Institutes in big cities will not find problem in getting students. Institutes in rural areas find very few takers.

These institutes do not get good teachers as most teachers would not like to shift from big cities to semiurban or rural areas," Shah said. He also attributed the downward trend in pharmacy to a dull job market. He said, on an average, a degree course student gets a salary package of Rs 60,000 to Rs 70,000 per annum. After post-graduation, they are offered Rs 1.2 lakh to Rs 2 lakh per year. With AICTE extending the course closure application deadline to February 27, more applications are likely, said GTU officials.

Note: The news item as being reproduced from the other source are for informational purpose only. Pharma Literati have not confirmed the accuracy of the news.


The Truth About Generic Vs. Brand-Name Medications

C. Michael White, Pharm.D., Professor and Head, Department of Pharmacy Practice, University of Connecticut explores the generic medicines practice in the recent interview in The Huffington Post.
There has been a lot of debate about the use of generic drugs vs. brand names. Are generics really as effective? It pays to be informed since, according to the FDA, “nearly 8 in 10 prescriptions filled in the United States are for generic drugs. The use of generic drugs is expected to grow over the next few years as a number of popular drugs come off patent through 2015.”
The excerpts :
Q: Why are brand names so much more expensive than generics?
Unlike the generic manufacturer, the original pharmaceutical company has to pay for more than just the actual production of that medication. The Tufts Center for the Study of Drug Development estimates that the cost to develop and win marketing approval for a new drug is $2.6 billion.
Q: What happens when a brand name goes generic?
At the end of an approximately seven-year period of exclusivity, the FDA allows one specific generic to be the first to market. That generic is given a period of time of exclusivity for about six months. At the end of that time period, any manufacturer that can prove that it can achieve the same drug concentrations in the blood that the brand name does can make a generic. Manufacturers of generics aren’t required to do studies in people to prove safety. It is assumed that if they can achieve same blood concentration, they will achieve same results."
Q: Do generics have to have the same recipe, effect, side effects?
They are very similar in terms of the active ingredient. According to the FDA, generic drugs do not need to contain the same inactive ingredients as the brand name product.
Q: So, will you always achieve the same effect with a generic as with a brand name?
Keep in mind that there is a lot of diversity among people. When they do the blood concentration studies, they do them in “average” people, but because the inactive ingredients and process of manufacturing are different, they can’t assure that everyone will achieve same blood concentrations.

Teixobactin_The new antibiotic

Teixobactin skeleton
The discovery of a new antibiotic called Teixobactin was announced by international team of researchers, in January this year. It is the most significant new antibiotic to be discovered in more than 30 years, and it may help combat the growing number of drug-resistant bacteria.
However, there are reasons why the discovery of this “game-changing” antibiotic is far more significant than the media has generally portrayed.
The first is because it was isolated from a bacterium that was previously unculturable. Bacterial chemistry and metabolism is so diverse, flexible and complex that their vital growth factors are often totally unknown. So, until now, it has been impossible to grow colonies of most of them in the lab for experimentation.
The startling situation is that microbiologists tell us that most bacteria – an estimated 99% – are currently regarded as unculturable. Thus this discovery opens the door, even if only a chink, to a vast new untapped resource for medicine, especially new antibiotics.  
For details, please read the complete story.

Saturday, 21 February 2015

Pharma academic research - Indian patent applications published on 20th February 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
For details of these patents, please write back to us at
Indian patent applications published on 20th February 2015

Application No
Composition comprising herbal extract of Jatropha Integerrima Jacq and
uses thereof
2398/DEL/2013 A
1) Prof. Surendra Kumar Sharma
2) Harneet Singh
Guru Jambheshwar University of Science and Technology, Hisar
Rivastigmine and Quercetin conjugate form for treatment of alzheimer's
2414/DEL/2013 A
1) Deepshikha Pande Katare
2) Kumud Bala
3) Puneet Kacker
4) Ruchi Jakhmola
Amity University

Friday, 20 February 2015

New Horizons in Drug Design

L M College Of Pharmacy is organizing three-days national seminar and Workshop on  "New Horizons in Drug Design."
This is broadly medicinal chemistry based interactive seminar for M. Pharm./Ph.D. students and faculty members who have zeal to know the essentials of structure-based and ligand-based drug design.

The key features include,
- Interactive talks on Drug Design by renowned speakers
- Hands on training on Schrodinger Suite
The details are as follows:

Theme:             New Horizons in Drug Design.

Dates:               1st to 3rd March 2015.

Organized by:   L M College Of Pharmacy. 

Location:           Ahmedabad.

Festive De Pharma

Uka Tarsadia University's Maliba Pharmacy College is organizing Festive De Pharma, a pharmacy festival which includes competitions on,

- Poster competition
- Oral presentation
- Pharma modelling
- Bookees
- Case studies
- Pharma Marketing
- Debate and
- Scitoons.

The details are as follows:

Theme:             Festive De Pharma.

Dates:               10th March 2015.

Organized by:   Maliba Pharmacy College, Uka Tarsadia University.

Location:           Bardoli, Gujarat.

Details available at:


Thursday, 19 February 2015

Pharma companies blame archaic law for lack of swine flu drugs

Today's economic times reports about the current issues related to swine flu drugs and the problems therein.

Drug makers in India have blamed an "archaic" health ministry regulation for the shortage of medicines used for treating swine flu, saying they had to destroy stockpiles of the drugs because chemists were reluctant to procure them.

More than 600 people have died of the disease across the country in the past two months.

Many patients, even in bigger cities like Delhi, have complained of lack of swine flu medicines at drug stores and hospitals. "Since the drug comes under Schedule X, there are various licences required to stock the medicines, which dissuades chemists to stock them," said an executive at Mumbai-based Cipla, which manufactures swine flu drug under the brand name Anti Flu. "And, if chemists are seen selling swine flu drugs without adequate licences, they immediately face prosecution."

Schedule X classifies "restrictive drugs" under the Drugs and Cosmetics Act of India, which imposes limitations on their sale by pharmacies and hospitals. Narcotics drugs, for example, are classified as Schedule X.

The government intention behind including swine flu drugs under Schedule X was to prevent their incessant use, which could make the disease immune to the drug.

"There was no demand for swine flu medicines throughout last year, because of which we had to destroy lakhs of batches as they had expired," said Adar Poonawala, managing director, Serum Institute of India. "Even chemists were reluctant to buy the medicines from us because there was no demand." Oseltamivir and Zanamavir are two key drugs used for treating swine flu. They are manufactured by drug companies such as Cipla, Natco, Hetero and Ranbaxy Laboratories. Besides, Serum Institute of India manufactures vaccines in the name of Nasovac and Nasovac S, which can also be used as preventive drugs.

Poonawala said it is also the responsibility of the health ministry to purchase the vaccines and keep the demand cycle going. "However, right now, we are back on our production cycle and ready with the new batch, so there is no shortage from our end," Poonawala added.

Pharma needs the right prescription

Kavita Khanna, the International Director, Bharat Serum and Vaccines writes about the pharma industry and  NDA Government’s hallmark ‘Make in India’ programme in Business Line.
The existing three-tier review system for obtaining product approval should be simplified as in US and Europe.
The NDA Government’s hallmark ‘Make in India’ programme can potentially be a game-changer in fulfilling Prime Minister Narendra Modi’s dream of transforming the currently anaemic $2 trillion economy into a $20 trillion power house.
Achieving this vision would necessitate a sustained, year-on-year growth of 9 per cent going forward. The pharmaceuticals and biotechnology sectors can play a significant role in this growth story if the government institutes a single-window clearance system for regulatory licenses.
The growth targets set for India’s healthcare sector are nothing new. The drivers of this growth – low-cost labour, technical skills and scientific excellence, all backed by a robust product patent regime – have existed for decades. Yet, the sector has not been able to actualise its innate potential. One of the major reasons is the contradictions built into the regulatory system.
The need of the hour is a top-to-bottom restructuring of the convoluted framework that regulates the introduction and manufacture of novel and generic drugs in India. This step is critical to get newer, cheaper and more effective medicines to the market much faster than what is possible now. It is instructive to take a look at how the system currently works.


Monday, 16 February 2015

Pharma academic research - Indian patent applications published on 13th February 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the academic research institutes in India go un-noticed.
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
For details of these patents, please write back to us at
Indian patent applications published on 13th February 2015
Application No
Aerosol formulation for the treatment of arthritis
1864/CHE/2012 A
1) Dr. Rajasekaran Aiyalu
2) Dr. Arulkumaran Govindarajan
3) Mr. Arivukkarasu Ramasamy
4) Mr. Ithayaventhan Subramaniam
5) Dr. Subramaniam Thayappan
KMCH College of Pharmacy,
Synthesis and anti inflammatory activity of Piperazine nucleus
containing novel Chalcone derivatives
3560/CHE/2013 A
1) Abdul Rahaman Shaik
2) Prameela Rani Avula
3) Rajendra Prasad Y
4) Pusapati Madan Ranjit
5) Phanikumar Kola
Nirmala College
of Pharmacy, Guntur